The North America xenotransplantation market size was estimated at USD 1.26 billion in 2025 and is predicted to reach around USD 2.93 billion by 2035, expanding at a CAGR of 8.8% from 2026 to 2035. The North American market for xenotransplantation is accelerated by breakthroughs in multi-gene CRISPR editing, human donor organ shortages, and pivotal clinical trial clearances by the U.S. FDA.

North America Xenotransplantation Market Statical Scope

In August 2025, the National Kidney Foundation reported that the U.S. Food and Drug Administration (FDA) approved the first clinical trials for kidney xenotransplantation in the U.S. The National Kidney Foundation is the leading patient advocacy organization in kidney health.

The American Kidney Fund implied that more than 557,000 patients in the U.S. are on dialysis to filter their blood when their kidneys are not functioning well enough to do so. The North American industry has shifted to human clinical translation, which is backed by specific support of the U.S. FDA for clinical trials .

North America Xenotransplantation Market Share, By Type, 2025 (%)

• Transplant Diagnostics- The transplant diagnostics segment dominated the market in 2025, with a share of 41%, owing to the growing adoption of diagnostic technologies for transplant compatibility and monitoring. The advanced diagnostic workflows have adopted highly specialized and real-time tools that are essential to support early-stage human clinical trials.
• Organ Preservation Solutions- The organ preservation solutions segment held a 36% share and is expected to grow in the coming years, driven by increasing demand for maintaining organ viability during transplantation procedures. These solutions are expanding due to the technical demands of maintaining the cellular integrity of genetically modified animal organs.
• Tissue Products- The tissue products segment held a 23% share and is expected to grow in the upcoming period due to rising applications of xenogeneic tissues in regenerative and transplant procedures. There is a wide use of animal-derived tissue products such as skin grafts, heart valves, porcine corneas, and acellular tissue scaffolds.

North America Xenotransplantation Market Share, By Application, 2025 (%)

• Kidney - The kidney segment dominated the market in 2025, with a share of 44%, supported by the growing prevalence of renal disorders and organ shortages. The major growth drivers for the kidney xenotransplantation are genetic engineering, CRISPR technology, targeted immunosuppression, scalable, and on-demand supply.
• Heart- The heart segment held a 38% share and is expected to grow in the coming years, driven by increasing research and transplantation demand for cardiac replacement solutions. A severe shortage of human donor hearts, advanced CRISPR Cas9 gene editing, tailored immunosuppressive therapies, and specialized perfusion techniques are driving the demand for xenotransplantation in heart treatment.
• Other Organs- The other organs segment held a 18% share and is expected to grow in the upcoming period due to additional xenotransplantation applications across multiple organ types. The progress of xenotransplantation across different organs and tissues is due to its applications for liver, lungs, pancreatic islet cells, corneas, and skin tissues.

Recent Developments in the North America Xenotransplantation Market

• In February 2025, the United Therapeutics Corporation announced the U.S. FDA clearance of its investigational new drug application for the UKidney xenotransplantation clinical trial. With this launch, it aims to expand the availability of transplantable organs to offer a therapeutic alternative to a lifetime on dialysis for a large patient population and to offer an allogeneic kidney transplant.

Competitive Landscape

The top companies and organizations in the xenotransplantation market in North America are United Therapeutics Corporation, eGenesis, Makana Therapeutics, XenoTherapeutics, and Miromatrix Medical. They are shaping their presence in the market by focusing on clinical trials, gene editing advancements, and organ preservation. The top offerings are genetically edited pig organs, clinical trials for kidney transplantation, cellular therapies, heart and liver xenotransplantation, and ex vivo machine perfusion technology.

Segments Covered in the Report

By Type

• Organ Preservation Solutions
• Transplant Diagnostics
• Tissue Products

By Application

• Heart
• Kidney
• Other Organs